Prostate Cancer Diagnostics Market – By Test Type, By Cancer Type, End Use & Forecast, 2024 – 2032

Prostate Cancer Diagnostics Market Size

The global prostate cancer diagnostics market was valued at USD 4.5 billion in 2023 and is expected to exhibit growth at a CAGR of 10.5% from 2024 to 2032. The strong market growth is driven by the increasing prevalence of prostate cancer, heightened awareness of associated risk factors, ongoing technological advancements, and rising investments in the development of innovative diagnostic modalities. These factors collectively support the expansion of the market.
 

The increasing prevalence of prostate cancer, particularly among aging populations, has heightened the demand for timely and accurate diagnostics. For instance, according to the American Cancer Society, it is estimated that new cases of prostate cancer will reach 299,010 by 2024 in the U.S. Further, public health initiatives and awareness campaigns by governments and organizations are encouraging more men to undergo routine screenings, accelerating market growth. Additionally, the shift toward early-stage detection and personalized treatments is fostering the need for advanced diagnostic tools.
 

Technological advancements play a significant role in driving market expansion. The adoption of innovative tools such as liquid biopsy, artificial intelligence (AI) in diagnostic imaging, and more accurate PSA tests are improving early cancer detection. These advancements provide better diagnostic accuracy and non-invasive alternatives, attracting both patients and healthcare providers. Moreover, increased healthcare spending and improved diagnostic infrastructure, especially in developed countries, have led to greater accessibility and adoption of these cutting-edge diagnostic methods.
 

Prostate cancer diagnostics refers to the methods and technologies used to detect the presence of cancerous cells in the prostate gland. The process involves screening tests like the Prostate-Specific Antigen (PSA) test, diagnostic imaging, biopsies, and advanced molecular diagnostics. These tools help healthcare providers identify the stage, type, and extent of prostate cancer, enabling tailored treatments and better patient outcomes.
 

Prostate Cancer Diagnostics Market Trends

Continual research and introduction of new technologies is expected to reshape the industry in years to come. One significant trend is the increasing adoption of liquid biopsy. This non-invasive test allows for the detection of cancerous DNA or biomarkers in bodily fluids like blood or urine, reducing the need for invasive procedures.
 

• Artificial intelligence (AI) integration is also gaining traction, aiding radiologists and clinicians in interpreting diagnostic images and PSA levels more accurately. AI-enhanced imaging helps detect early-stage tumors that may be missed by conventional techniques, improving diagnosis rates. Additionally, genomic testing is revolutionizing the field by enabling personalized treatment plans based on a patient’s genetic profile, particularly in high-risk patients with hereditary prostate cancer.
   
• At-home testing kits are another trend making diagnostics more accessible to a wider demographic, as these allow men to conduct preliminary screening tests without visiting a clinic. Lastly, the shift towards value-based healthcare is leading to more efficient diagnostic solutions, pushing companies to develop products that reduce diagnostic time and improve patient care while minimizing costs.
   

Prostate Cancer Diagnostics Market Analysis

Based on test type, the market is classified into diagnostic tests and imaging tests. The diagnostic tests generated the highest revenue of USD 2.9 billion in 2023.
 

• Diagnostic tests hold a significant share of the market due to their critical role in early detection. The most commonly used diagnostic test, the PSA test, measures the level of prostate-specific antigen in the blood, which is a key indicator of prostate cancer. This test is widely used in routine health check-ups and screenings, especially in high-risk populations such as men above the age of 50. With advancements in PSA testing, including highly sensitive assays, diagnostic tests remain an essential part of prostate cancer detection protocols.
   
• Furthermore, biopsy and imaging tests are vital for confirming prostate cancer diagnosis. While PSA tests are used for initial screening, biopsies are necessary for the definitive diagnosis of cancer. Imaging techniques such as MRI and CT scans are used to assess the extent of cancer spread, aiding in treatment planning. The high reliance on these diagnostic tests by clinicians, coupled with improvements in accuracy, is expected to drive the segment's growth in the coming years.
   

Based on cancer type, the prostate cancer diagnostics market is categorized into prostatic adenocarcinoma, small cell carcinoma, and other prostate cancer types. The prostatic adenocarcinoma segment generated the highest revenue of USD 4.1 billion in 2023.
 

• Prostatic adenocarcinoma dominates the market, accounting for the vast majority of prostate cancer cases. Over 95% of prostate cancers are adenocarcinomas, which develop in the gland cells of the prostate. The high prevalence of this cancer type is a significant factor driving the demand for diagnostic tools specifically designed to detect adenocarcinoma. As the most common form of prostate cancer, adenocarcinoma is the leading cause of prostate cancer-related deaths, further underscoring the importance of accurate and early diagnosis.
   
• Moreover, advanced diagnostic technologies tailored to adenocarcinoma, such as genomic testing, are gaining popularity. These tests provide insights into the genetic mutations driving cancer progression, offering opportunities for personalized treatments. As genomic testing becomes more accessible, it is anticipated to play an even more prominent role in the detection and management of prostatic adenocarcinoma.  
   

Based on end-use, the prostate cancer diagnostics market is segmented into hospitals, diagnostic laboratories, cancer research institutes, and other end-users. The hospital segment dominated the market in 2023 and is anticipated to reach USD 4.9 billion by 2032.
 

• Hospitals are the largest end-users in the market due to their comprehensive diagnostic capabilities. Hospitals typically offer a full suite of diagnostic services, from PSA testing to advanced imaging and biopsy procedures. The availability of cutting-edge diagnostic tools, coupled with multidisciplinary teams of oncologists, radiologists, and pathologists, makes hospitals the preferred setting for prostate cancer diagnosis. This is especially true for high-risk or advanced cases, where multiple diagnostic methods are needed to assess the cancer’s progression and inform treatment options.
   
• Moreover, hospitals often house research and clinical trials for new prostate cancer diagnostics and treatments. This encourages the adoption of innovative diagnostic technologies, further solidifying hospitals dominant position in the market.
   

North America prostate cancer diagnostics market accounted for USD 1.8 billion market revenue in 2023 and is anticipated to grow at a CAGR of 9.9% between 2024 and 2032.

• The market in North America is growing rapidly due to high awareness levels and advanced healthcare infrastructure. The region’s increasing aging population, coupled with regular prostate cancer screening programs, drives demand for diagnostics. Additionally, regulatory support from agencies like the FDA enables faster adoption of innovative diagnostic tools, such as liquid biopsy and genetic testing.
   
• Moreover, public health initiatives, such as those promoted by the American Cancer Society, encourage early screening, contributing to the market's expansion. Moreover, high healthcare spending and reimbursement policies for diagnostic tests boost market growth.
   

U.S. prostate cancer diagnostics market accounted for USD 1.7 billion market revenue in 2023 and is estimated to hold a substantial share between 2024 to 2032.
 

• The growth of prostate cancer diagnostics in the U.S. is largely driven by the high prevalence of the disease, making it one of the most common cancers among men. Further, increased awareness of prostate cancer, backed by campaigns from healthcare organizations, has led to more regular screenings. For instance, in August 2023, the George Washington University (GW) Cancer Center launched a prostate cancer awareness campaign. This health awareness social media toolkit could help cancer control organizations use evidence-based strategies to detect prostate cancer.
   
• Moreover, higher healthcare spending and investment in research for better diagnostic tools contribute to market expansion. Together, these factors result in a growing demand for prostate cancer diagnostics in the U.S.
   

UK prostate cancer diagnostics market is projected to grow remarkably in the coming years.
 

• The growth of UK market is attributed to the growing incidence of prostate cancer, which is fueling the demand for diagnostics. National health initiatives like Prostate Cancer UK’s awareness campaigns have significantly increased public participation in prostate cancer screenings, particularly among older men. The National Health Service (NHS) also offers free PSA testing for at-risk populations, making early diagnosis more accessible.
   
• The UK government’s emphasis on improving cancer detection rates has also driven the adoption of advanced diagnostic technologies, such as MRI-guided biopsies. These efforts, along with research initiatives, position the UK as a key market for prostate cancer diagnostics.
   

Japan holds a dominant position in the Asia Pacific prostate cancer diagnostics market.
 

• In Japan, the rising elderly population is a key driver of market growth. The country has one of the fastest-aging populations globally, increasing the prevalence of age-related diseases like prostate cancer. The Japanese government has also implemented cancer screening programs aimed at promoting early detection among older men, further boosting demand.
   
• Japan's healthcare system is highly advanced, and hospitals are adopting cutting-edge diagnostic imaging services, including AI-assisted imaging and liquid biopsy. This trend, along with increasing awareness of prostate cancer, is pushing the market forward in Japan.
   

Prostate Cancer Diagnostics Market Share

The market is characterized by the presence of several key players and a focus on technological innovation and strategic partnerships. In recent years, several market players have launched innovative products. For instance, Siemens Healthineers introduced advanced molecular diagnostic solutions that streamline the detection of prostate cancer. Other major players, such as Roche and Myriad Genetics, are expanding their product portfolios by integrating genomic testing to enhance prostate cancer detection capabilities.
 

Prostate Cancer Diagnostics Market Companies

Prominent players operating in the prostate cancer diagnostics industry include:

• Abbott Laboratories
• AdvaCare Pharma
• Beckman Coulter, Inc. (Danaher Corporation)
• Becton, Dickinson and Company
• BIOMÉRIEUX
• F. Hoffmann-La Roche Ltd.
• FUJIFILM Holdings Corporation
• GE Healthcare Technologies Inc.
• Glycanostcs Ltd.
• Healgen
• KOELIS
• Koninklijke Philips N.V.
• Metamark Genetics, Inc.
• miR Scientific
• Myriad Genetics, Inc.
• Proteomedix
• Siemens Healthineers AG
• Veracyte
   

Prostate Cancer Diagnostics Industry News:

• In December 2023, Proteomedix AG, announced its acquisition by U.S. based Blue Water Biotech Inc. through a share exchange transaction. The merged entity, now named Onconetix Inc., combines two commercial-stage products focused on diagnosing prostate cancer and treating benign prostatic hyperplasia.
   
• In August 2023, Myriad Genetics, Inc. announced the integration of Absolute Risk Reduction (ARR) into the Prolaris Prostate Cancer Prognostic Test to help patients and providers make personalized treatment decisions regarding hormone therapy. This product launch helped the company in enhancing its diagnostic portfolio and acquire an increased customer base.
   

The prostate cancer diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Diagnostics tests
  • PSA
  • Prostate biopsy
  • Molecular/ genomic test
  • Other diagnostics tests
• Imaging tests
  • Transrectal ultrasound (TRUS)
  • MRI
  • CT scan
  • Other imaging tests

Market, By Cancer Type

• Prostatic adenocarcinoma
• Small cell carcinoma
• Other prostate cancer types

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Cancer research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Poland
  • Sweden
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Chile
  • Peru
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Iran
  • Israel
  • Rest of MEA